Immune checkpoint inhibitors (ICIs) have become a mainstay of treatment within the field of oncology for multiple types of cancer. However, as the utilization of ICIs has expanded over recent years, so too has the incidence of immune-related adverse events (irAEs). Health care practitioners in the non-oncology care setting, including pharmacists, are often challenged to recognize irAEs due to the wide variation in onset, severity, and symptomatology, leaving patients at risk for worse outcomes. It is imperative that pharmacists practicing in the non-oncology setting recognize patients at risk for developing an irAE and connect them with appropriate treatment.
In this CME Outfitters BriefCase, expert faculty will guide learners through a case involving a patient who presents with escalating symptoms of an irAE over multiple visits. In this program, particular emphasis will be placed on recognizing the manifestations, frequency, risk factors, and timeline for the development of irAEs in the non-oncology setting.
At the end of this CME/CE activity, participants should be able to evaluate patients for potential irAE development in non-oncology settings.
Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Pharmacists in outpatient, ambulatory, or community care settings
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Reynolds reports the following financial relationships: Research Support: Investigator initiated research from Boston Scientific Corporation; Stock Shareholder (ownership interest): Biogen; Other Financial or Material Support: Teledoc Health, Inc.
Dr. McPherson reports the following financial relationships: Research Support: Hitachi, Ltd.
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.